期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀在慢性肾功能不全患者中的应用 被引量：2

Applications of Statins in Patients with Chronic Kidney Disease
下载PDF
导出
摘要 慢性肾功能不全患者的总体死亡风险和心血管疾病死亡风险较之普通人群都有显著提高,该类患者血脂的质和量都存在异常。他汀具有降低胆固醇、抗炎、抗氧化以及稳定现有斑块等作用。现就他汀在慢性肾功能不全患者中的疗效观察进行综述,并且介绍他汀在临床应用方面的最新进展。 Patients at all stages of chronic kidney disease （CKD） have a significantly elevated risk of all-cause and cardiovascular mortality compared with the general population. The lipid profile shows both qualitative and quantitative abnormalities in patients with CKD. The use of statins results in lipid-lowering, anti-inflammation, anti-oxidation, and the stabilization of existing plaques. This review focuses on evidence showing the benefits of statin therapy in patients with CKD, and presents the latest progress of statins in clinical therapy.
作者 王锦溪 李虹伟 赵树梅
机构地区 首都医科大学第二临床医学院 首都医科大学附属北京友谊医院心血管中心
出处 《心血管病学进展》 CAS 2013年第1期66-68,共3页 Advances in Cardiovascular Diseases
关键词 他汀 血脂异常 慢性肾功能不全 statins lipid abnormalities chronic kidney disease
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献20

  • 1Navaneethan SD,Hegbrant J,Strippoli GFM. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease[J].Current Opinion in Nephrology and Hypertension,2011,(02):146.
  • 2Deshmukh A,Mehta JL. Statins and renal disease:friend or foe[J].Current Atherosclerosis Report,2011,(01):57-63.
  • 3Reiner ,Catapano AL,de Backer G. ESC/EAS guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J].European Heart Journal,2011,(14):1769-1818.
  • 4M(a)rz W,Genser B,Drechsler C. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J].Clin J Am Soc Nephrol,2011,(06):1316-1325.
  • 5Vaziri ND,Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease[J].Blood Purification,2011,(1-3):189-196.
  • 6Dalrymple LS,Kaysen GA. The effect of lipoproteins on the development and progression of renal disease[J].American Journal of Nephrology,2008,(05):723-731.doi:10.1159/000127980.
  • 7Matsushita K,van der Velde M,Astor B. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts:a collaborative meta-analysis[J].The Lancet,2010,(9731):2073.
  • 8Tonelli M,Keech A,Shepherd J. Effect of pravastatin in people with diabetes and chronic kidney disease[J].Journal of the American Society of Nephrology,2005,(12):3748-3754.
  • 9Navaneethan SD,Pansini F,Perkovic V. HMG CoA reductase inhibitors(statins)for people with chronic kidney disease not requiring dialysis[J].Cochrane Database of Systematic Reviews,2009,(02):CD007784.
  • 10Shepherd J,Kastelein JJP,Bittner V. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease::The TNT (Treating to New Targets) Study[J].Journal of the American College of Cardiology,2008,(15):1448-1454.

同被引文献14

  • 1Afkarian M,Katz M,Bansal N,et al.Diabetes,Kidney Disease,and Cardiovascular Outcomes in the Jackson Heart Study[J].Clin J Am Soc Nephrol,2016,6:23.
  • 2Riwanto M,Landmesser U.High density lipoproteing and endothelial functions:mechanistic insights and alterations in cardiovascular disease[J].Journal of lipid research,2013,54(12):3227-3243.
  • 3Gormley AK,et al.High-density lipoprotein migration and reendothelializatioe via scavenger receptor-B type I[J].Circ Ees,2006,98(1):63-72.
  • 4Liu D,Ji L,Zhang D,et al.Nonenzymatic glycation of high-density ipoprotein impairs its anti-inflammatory effects in innate immunity[J]. Diabetes Metab Pes lev, 2012,28(2): 186-196.
  • 5Shroff Speer T,Colin S,et al.HDL in children with CKD promotes endothelial dysfunction and an abnormat vascutar phenotype[J].Journat of the American Society of NephroloAy,2014 25(11). 2658-2568.
  • 6Hopkins PN.Molecularbiology of atherosclerosis[J].PhysioI Rev,2015, 95(3): 1517-1542.
  • 7Libby P.Inflammation in atherosclerosis[J].Arteriosclerosis Thrombosis a Vscutar Biotogy, 2000,48(2). 265-266.
  • 8Buckley ML,Ramji DP.The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atheroscierosfs[J].Biochfm Biophys Acta,2015,129(7):1498-1510.
  • 9Pateras I,Giaginis C,Tsigris C,et al.Theocharis S (2014) NF- kappaB signaling at the crossroads of inflammation and atherogenesis:searching for new therapeutic links[J].Expert Opin TherTargets, 2014, 18(9): 1089-1101.
  • 10Hansson GK,Robertson AK,Soderberg-Naucler C.Inflammation arid atherosclerosis,Annu[J].Annual ieview of Pathology Mechanisms of Pisease, 2006, 1 (1). 297-329.

引证文献2

二级引证文献1

心血管病学进展
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部